CKPT
Price
$4.02
Change
-$0.02 (-0.50%)
Updated
Apr 4, 04:39 PM (EDT)
Capitalization
339.24M
CYCC
Price
$0.21
Change
-$0.02 (-8.70%)
Updated
Apr 4, 03:28 PM (EDT)
Capitalization
50.48M
Ad is loading...

CKPT vs CYCC

Header iconCKPT vs CYCC Comparison
Open Charts CKPT vs CYCCBanner chart's image
Checkpoint Therapeutics
Price$4.02
Change-$0.02 (-0.50%)
Volume$445
Capitalization339.24M
Cyclacel Pharmaceuticals
Price$0.21
Change-$0.02 (-8.70%)
Volume$300
Capitalization50.48M
CKPT vs CYCC Comparison Chart
Loading...
CKPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CKPT vs. CYCC commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CKPT is a Buy and CYCC is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CKPT: $4.04 vs. CYCC: $0.23)
Brand notoriety: CKPT and CYCC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CKPT: 136% vs. CYCC: 46%
Market capitalization -- CKPT: $339.24M vs. CYCC: $50.48M
CKPT [@Biotechnology] is valued at $339.24M. CYCC’s [@Biotechnology] market capitalization is $50.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CKPT’s FA Score shows that 0 FA rating(s) are green whileCYCC’s FA Score has 1 green FA rating(s).

  • CKPT’s FA Score: 0 green, 5 red.
  • CYCC’s FA Score: 1 green, 4 red.
According to our system of comparison, both CKPT and CYCC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CKPT’s TA Score shows that 3 TA indicator(s) are bullish while CYCC’s TA Score has 4 bullish TA indicator(s).

  • CKPT’s TA Score: 3 bullish, 7 bearish.
  • CYCC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CYCC is a better buy in the short-term than CKPT.

Price Growth

CKPT (@Biotechnology) experienced а +0.25% price change this week, while CYCC (@Biotechnology) price change was -24.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.76%. For the same industry, the average monthly price growth was -16.64%, and the average quarterly price growth was -18.24%.

Reported Earning Dates

CKPT is expected to report earnings on May 15, 2023.

CYCC is expected to report earnings on Mar 27, 2024.

Industries' Descriptions

@Biotechnology (-10.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CKPT($339M) has a higher market cap than CYCC($50.5M). CKPT YTD gains are higher at: 26.250 vs. CYCC (-38.830). CYCC has higher annual earnings (EBITDA): -15.47M vs. CKPT (-37.51M). CKPT has more cash in the bank: 4.7M vs. CYCC (2.98M). CYCC has less debt than CKPT: CYCC (0) vs CKPT (2.47M). CYCC has higher revenues than CKPT: CYCC (74K) vs CKPT (47K).
CKPTCYCCCKPT / CYCC
Capitalization339M50.5M671%
EBITDA-37.51M-15.47M243%
Gain YTD26.250-38.830-68%
P/E RatioN/AN/A-
Revenue47K74K64%
Total Cash4.7M2.98M158%
Total Debt2.47M0-
FUNDAMENTALS RATINGS
CKPT vs CYCC: Fundamental Ratings
CKPT
CYCC
OUTLOOK RATING
1..100
2956
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3595
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCC's Valuation (23) in the Biotechnology industry is significantly better than the same rating for CKPT (93) in the Pharmaceuticals Major industry. This means that CYCC’s stock grew significantly faster than CKPT’s over the last 12 months.

CYCC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CKPT (100) in the Pharmaceuticals Major industry. This means that CYCC’s stock grew similarly to CKPT’s over the last 12 months.

CYCC's SMR Rating (100) in the Biotechnology industry is in the same range as CKPT (100) in the Pharmaceuticals Major industry. This means that CYCC’s stock grew similarly to CKPT’s over the last 12 months.

CKPT's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for CYCC (95) in the Biotechnology industry. This means that CKPT’s stock grew somewhat faster than CYCC’s over the last 12 months.

CKPT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CYCC (100) in the Biotechnology industry. This means that CKPT’s stock grew similarly to CYCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CKPTCYCC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
86%
Bullish Trend 9 days ago
83%
Declines
ODDS (%)
Bearish Trend 30 days ago
86%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CKPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBCCX14.52N/A
N/A
Gabelli Dividend Growth C
PRACX43.58N/A
N/A
Putnam Research C
MSCRX10.55N/A
N/A
Madison Small Cap R6
TICHX25.71N/A
N/A
Nuveen Large Cap Responsible Eq I
QCLVX31.87N/A
N/A
Federated Hermes MDT Large Cap Value C